{
    "nctId": "NCT00063102",
    "briefTitle": "A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.",
    "officialTitle": "A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Objective Response Rate in subjects with Breast cancer",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Stage IIIB or IV breast cancer.\n* Recurrent tumor after or while on taxane therapy (taxol or taxotere).\n* Able to tolerate normal activities of daily living.\n* Adequate bone marrow, kidney and liver function.\n\nExclusion Criteria\n\n* Pregnant or breast feeding.\n* No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}